We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biogen has announced that the European Commission (EC) has granted marketing authorisation for Vumerity® (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).